DIPTHERIA,TETANUS, PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE (Adsorbed) 0.5mL Suspension for In Philippines - English - FDA (Food And Drug Administration)

diptheria,tetanus, pertussis, hepatitis b and haemophilus influenzae type b conjugate vaccine (adsorbed) 0.5ml suspension for in

medical vaccines online deliveries - diptheria,tetanus, pertussis, hepatitis b and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection im - 0.5ml

ComBE Five (Liquid) Namibia - English - Namibia Medicines Regulatory Council

combe five (liquid)

m/s bilogical e. limited - diptheria, tetanus, pertussis (whole cell), hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection - each dose of 0.5ml contains diptheria toxoid 25 lf (?30 iu), tetanus toxoid 5.5 lf (?60 iu), b. pertussis 16 iou (?4 iu), r-hbs

Hexavac European Union - English - EMA (European Medicines Agency)

hexavac

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

None Suspension for Injection (IM) Philippines - English - FDA (Food And Drug Administration)

none suspension for injection (im)

n/a; importer: medical vaccines online deliveries; distributor: medical vaccines online deliveries - diphtheria, tetanus, pertussis, hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diptheria toxoid.............<25 lfl> 30 i.u.) tetanus toxoid.............> 2.5 lf> 40 i.u.) . bordetella pertussis (whole cell)............< 16 ou (>4 1.u.) . hepatitis b (rdna)....................10 mcg haemophilus influenzae congugate vaccine............ > 10 mcg

DIPTHERIA; HAEMOPHILUS TYPE B; HEPATITIS B; PERTUSSIS; TETANUS Zimbabwe - English - Medicines Control Authority

diptheria; haemophilus type b; hepatitis b; pertussis; tetanus

m/s biological e, ltd - diptheria; haemophilus type b; hepatitis b; pertussis; tetanus - vaccine - 0.5ml (10 dose)

DIPTHERIA; HAEMOPHILUS TYPE B; HEPATITIS B; PRTUSSIS; TETANUS Zimbabwe - English - Medicines Control Authority

diptheria; haemophilus type b; hepatitis b; prtussis; tetanus

m/s biological e, ltd - diptheria; haemophilus type b; hepatitis b; pertussis; tetanus - vaccine - 0.5ml

TRIPACEL pertussis vaccine Australia - English - Department of Health (Therapeutic Goods Administration)

tripacel pertussis vaccine

sanofi-aventis australia pty ltd - pertussis filamentous haemagglutinin, quantity: 10 microgram/ml; pertussis fimbriae 2 + 3, quantity: 10 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis toxoid, quantity: 20 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 6 microgram/ml - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; phenoxyethanol - tripacel is indciated for primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. tripacel is also indicated for the fourth and fifth dose for children from 15 months of age up to their eighth birthday who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines.

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms / 0.5mL, suspension for injection, vial Australia - English - Department of Health (Therapeutic Goods Administration)

gardasil 9 human papillomavirus 9-valent vaccine, recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms / 0.5ml, suspension for injection, vial

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: polysorbate 80; aluminium; histidine; sodium chloride; borax; water for injections - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5mL, suspension for injection, syringe Australia - English - Department of Health (Therapeutic Goods Administration)

gardasil 9 human papillomavirus 9-valent vaccine, recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5ml, suspension for injection, syringe

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: sodium chloride; histidine; borax; aluminium; water for injections; polysorbate 80 - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

ADACEL POLIO pertussis vaccine Australia - English - Department of Health (Therapeutic Goods Administration)

adacel polio pertussis vaccine

sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.